Introduction Asthma is a chronic respiratory disorder requiring ongoing medical management. This ecological study ...
Objective Systemic corticosteroids for 5–7 days are standard care for asthma exacerbations, but the optimal duration and ...
Reductions in airway hyperresponsiveness and suppressed eosinophilic response at both 6 weeks and 12 weeks observed after a ...
Generate:Biomedicines to begin global phase 3 studies of GB-0895, a long-acting anti-TSLP antibody for severe asthma engineered with AI: Somerville, Massachusetts Tuesday, Decembe ...
SOLAIRIA-1 and SOLAIRIA-2 will evaluate GB-0895 in approximately 1,600 patients with severe asthma whose disease remains ...
A new study offers some of the first evidence that this weather-related condition is a concern in the United States. But there are ways to lower the risk. A new study suggests that severe ...
Tezepelumab yielded the greatest reduction in exacerbations in patients with moderate‑to‑severe allergic asthma, whereas dupilumab yielded superior improvement in lung function, a meta-analysis showed ...
CHICAGO -- A series of large, real-world analyses supported benefit of GLP-1 receptor agonists in cardiopulmonary indications for patients with type 2 diabetes, researchers reported at the CHEST ...
With the inclusion of the BATURA study, Airsupra has now demonstrated its effectiveness in reducing the risk of severe exacerbations across all severity levels of asthma vs albuterol. The Food and ...
Only 15% of patients were adherent to ICS therapy 3 months after their asthma exacerbation, and less that one-fourth of those remained adherent 9 months later. Improved adherence to inhaled ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback